GlassScriptPhysician profile
Jasmeet Gill
NPI 1730534306
$3,682.79
in general payments reported to CMS, 2019-2025
30 companies · $816 in 2025
The $816 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $240 · 2021: $413 · 2022: $318 · 2023: $666 · 2024: $852 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $624.19 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $339.76 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $278.92 | 2024-2025 | Krystexxa, Tavneos |
| Alexion Pharmaceuticals, INC. | $256.07 | 2019-2024 | Ultomiris |
| Fresenius USA Marketing, INC. | $237.06 | 2022-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $220.38 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $167.59 | 2021-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $166.32 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $158.35 | 2023-2025 | |
| Ardelyx, INC. | $147.35 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $133.74 | 2019-2024 | Veltassa |
| Glaxosmithkline, LLC. | $119.47 | 2022-2024 | Benlysta |
| Nxstage Medical, INC. | $113.07 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.86 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $73.47 | 2022-2025 | Ozempic, Rybelsus |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $72.33 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $65.35 | 2021-2025 | Acthar |
| Recor Medical INC | $60.61 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $44.10 | 2024-2025 | |
| La Jolla Pharmaceutical Company | $40.92 | 2020 | |
| Pfizer INC. | $38.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.64 | 2021 | |
| Calliditas Therapeutics US INC. | $29.28 | 2023-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $28.85 | 2019 | |
| Ani Pharmaceuticals, INC. | $28.14 | 2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $23.03 | 2025 | |
| Akebia Therapeutics INC | $20.24 | 2022 | |
| Merck Sharp & Dohme LLC | $18.32 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.58 | 2022 | |
| Cranial Technologies, INC | $13.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmeet Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.